NCT04501276 - A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

January 17, 2024

Study Completion Date

February 1, 2025

Conditions

Advanced/Metastatic Solid Tumors

Interventions

DRUG

ADG116

For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.

DRUG

ADG106

For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.

DRUG

anti PD1 drug

For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.

Trial Locations (4)

78229

Next Oncology, San Antonio

Unknown

Ashford Cancer Centre Research, Kurralta Park

Cabrini Hospital, Malvern

Macquarie University, Sydney